Hjem › Kronisk myelomonocytisk leukemi › California
Kliniske studier for Kronisk myelomonocytisk leukemi i California
12 studier for Kronisk myelomonocytisk leukemi søker deltakere på steder i California.
Byer i California
Offisiell studietekst (engelsk)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- City of Hope Comprehensive Cancer Center, Duarte
- UCLA Medical Center, Los Angeles
- Stanford Cancer Institute, Stanford
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT04996875TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
- Stanford University, Palo Alto
RekruttererFase 1
Alder 18 til 80 · Alle kjønn · Oppdatert 17. aug. 2026 · NCT07302776Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- Kaiser Permanente San Diego, San Diego
- Allergy & Asthma Clinical Research of the Bay Area, Walnut Creek
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 12. aug. 2026 · NCT07143669Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- City of Hope Medical Center, Duarte
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT06815003A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Keck School of Medicine of USC, Los Angeles
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT04256317A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- City of Hope, Duarte
- Stanford, Palo Alto
RekruttererFase 2
Alder 18 til 66 · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- City of Hope, Duarte
- Stanford Medical Center, Palo Alto
RekruttererFase 1
Alder 12 og eldre · Alle kjønn · Oppdatert 16. mar. 2026 · NCT06994676Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- City of Hope Medical Center, Duarte
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mar. 2026 · NCT06543381A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- Stanford University, Stanford
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 9. feb. 2026 · NCT06950034Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- University of California Davis Health (UC Davis Health), Sacramento
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. jan. 2026 · NCT05184842Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- University of California Irvine, Irvine
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Stanford Cancer Center, Palo Alto
- og 1 flere
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2025 · NCT03850574Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- City of Hope, Duarte
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. apr. 2025 · NCT06462365Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.